• Immune checkpoint inhibitors show promise in oral cancer treatment. • Pembrolizumab and nivolumab offer new options for OSCC. • Immunotherapy targets immune checkpoints to fight OSCC. • Combining immunotherapy with other treatments enhances efficacy. • Challenges include managing immune-related adverse events in OSCC therapy.
No takes yet. Share an insight, caveat, or question.
Santosh Patil (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: